Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
22.53
-0.19 (-0.84%)
At close: Nov 25, 2025, 4:00 PM EST
22.53
0.00 (0.00%)
After-hours: Nov 25, 2025, 4:00 PM EST
Lyell Immunopharma Stock Forecast
Stock Price Forecast
The 3 analysts that cover Lyell Immunopharma stock have a consensus rating of "Buy" and an average price target of $16.67, which forecasts a -26.01% decrease in the stock price over the next year. The lowest target is $10 and the highest is $20.
Price Target: $16.67 (-26.01%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Lyell Immunopharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $10 → $20 | Hold | Maintains | $10 → $20 | -11.23% | Nov 24, 2025 |
| LUCID CAPITAL MARKETS | LUCID CAPITAL MARKETS | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | -11.23% | Sep 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $1 → $10 | Hold | Maintains | $1 → $10 | -55.61% | Jun 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $20 | Hold | Reiterates | $20 | -11.23% | Apr 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $20 | Hold | Reiterates | $20 | -11.23% | Mar 13, 2025 |
Financial Forecast
Revenue This Year
10.71K
from 61.00K
Decreased by -82.44%
Revenue Next Year
n/a
from 10.71K
EPS This Year
-11.71
from -26.23
EPS Next Year
-11.22
from -11.71
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 21,000 | n/a | |||
| Avg | 10,710 | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -65.6% | - | |||
| Avg | -82.4% | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -11.13 | -8.11 | |
| Avg | -11.71 | -11.22 | |
| Low | -12.09 | -13.69 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.